Pavan Reddy, M.D., is the Frances and Victor Ginsberg Professor of Hematology/Oncology and the Chief of the Division of Hematology/Oncology at the University of Michigan Medical School. He also serves as the Deputy Director for the University of Michigan Rogel Cancer Center.
A physician-scientist who does both bench and translational research, his work is focused on understanding the role of immune cells in blood diseases, cancer and transplantation. His groundbreaking research is supported by funding from the National Institutes of Health, the Leukemia and Lymphoma Society, and other foundations.
Dr. Reddy was born and raised in India. He earned his medical degree from Osmania University in Hyderabad in 1994 then came to the United States where he completed a residency in internal medicine at the University of Missouri in 1998. Following the completion of fellowships in hematology/oncology and bone and marrow transplantation at the University of Michigan, he joined the U-M faculty in 2002 and began to co-direct the Bone Marrow Transplant Program and the Hematologic Malignancies Program since 2011. He now serves as the Chief of the Division of Hematology/Oncology. He is the author or co-author of over 140 journal articles and book chapters. Dr. Reddy has received many honors, including the Jerome Conn Award from department of medicine, awards from national societies including the election to honorary societies such as American Society of Clinical Investigation (ASCI), Association of American Physicians (AAP), and American Clinical and Climatological Association (ACCA). He holds leadership roles in multiple scientific committees for the American Society of Blood and Marrow Transplantation and serves on NIH panels. He is an associate director for the journals Hematologica, Biology of Blood and Marrow Transplantation, and Bone Marrow Transplantation.
T-cell responses and DC biology
Dr. Reddy focuses on the immunobiology of T-cells and dendritic cells. His Lab utilizes several experimental models including those relevant to graft-versus-host disease (GVHD), a devastating immune response that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. Dr. Reddy hopes to translate the knowledge he gains through his research into powerful, lifesaving treatments for patients everywhere. His research has been continuously funded by the NIH with multiple grants for over 15 years.
- Fujiwara H, Docampo MD, Riwes M, Peltier D, Toubai T, Henig I, Wu SJ, Kim S, Taylor A, Brabbs S, Liu C,Zajac C, Oravecz-Wilson K, Sun Y, Núñez G, Levine JE, van den Brink M, Ferrara JLM, Reddy P. Microbial metabolite sensor GPR43 controls severity of experimental GVHD. Nature Communications. 2018 (In press).
- Wu SJ, Niknafs YS, Kim S, Oravecz-Wilson K, Zajac C, Toubai T, Sun Y, Prasad J, Peltier D, Fujiwara H, Hedig I, Mathewson N, Khoriaty R, Ginsburg D, Reddy P. A critical analysis of the role of SNARE protein SEC22B in antigen cross-presentation. Cell Reports Volume 19, Issue 13, p2645–2656, 27 June 2017.
- Mathewson N, Jenq R, Mathew AV, Koenigsknecht M, Hanash A, Toubai T, Oravecz-Wilson K, Wu S-R, Sun Y, Rossi C, Fujiwara H, Byun J, Shono Y, Lindemans C, Calafiore M, Schmidt TC, Honda K, Young VB, Pennathur S, Brink MVD, Reddy P. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nature Immunology, 2016 May;17(5):505-13.
- Sun Y, Oravecz-Wilson K, Mathewson N, Wang Y, McEachin R, Liu C, Toubai T, Wu J, Rossi C, Braun T, Saunders T, Reddy P. Mature T cell responses are controlled by microRNA-142. J Clin Invest. 2015 Jul 1;125(7):2825-40. PMCID: 26098216
- Sun Y, Tawara I, Zhao M, Qin ZS, Toubai T, Mathewson N, Tamaki H, Nieves E, Chinnaiyan AM, Reddy P. Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. J Clin Invest. 2013 Nov;123(11):4739-54. PubMed PMID: 24216511; PubMed Central PMCID: PMC3809794.
- Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan;15(1):87-95. PubMed PMID: 24295572; PubMed Central PMCID: PMC4103793.
- Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E, Azam T, Dinarello CA, Reddy P. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):564-9. PubMed PMID: 22203983; PubMed Central PMCID: PMC3258603.
- Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL.A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005 Nov;11(11):1244-9. PMID: 16227991